April 2015

Antiviral therapy with nucleoside analogs demonstrated an improvement in survival for sorafenib-treated patients with hepatitis B virus-related hepatocellular carcinoma.

Statin use was associated with a statistically significant reduction in the risk of liver cancer.

The risk of developing liver cancer may be increased by excessive body fat and decreased by coffee consumption.

Laura Dawson, MD, provides insight into the diagnosis and treatment of hepatocellular carcinoma.

A novel, evidence-based model for staging liver function in the setting of hepatocellular carcinoma may offer improved guidance in the selection of appropriate, patient-specific therapeutic strategies.

A recent phase III clinical trial has offered hope for the prophylactic management of hand-foot skin reaction in patients with hepatocellular carcinoma treated with sorafenib.

The small molecule multikinase inhibitor sorafenib remains the only molecularly targeted therapy approved by the FDA for the treatment of hepatocellular carcinoma, with ongoing clinical trials diligently testing the potential for novel targeted agents or combination therapies to further improve patient outcomes in this setting.